[go: up one dir, main page]

CN107674039A - A kind of preparation method than his western intermediate - Google Patents

A kind of preparation method than his western intermediate Download PDF

Info

Publication number
CN107674039A
CN107674039A CN201610614438.8A CN201610614438A CN107674039A CN 107674039 A CN107674039 A CN 107674039A CN 201610614438 A CN201610614438 A CN 201610614438A CN 107674039 A CN107674039 A CN 107674039A
Authority
CN
China
Prior art keywords
amino
benzylpentyl
preparation
phenyl
hydroxymethylthiazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610614438.8A
Other languages
Chinese (zh)
Inventor
李涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GYROCHEM (SHANGHAI PUYI) CO Ltd
Original Assignee
GYROCHEM (SHANGHAI PUYI) CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GYROCHEM (SHANGHAI PUYI) CO Ltd filed Critical GYROCHEM (SHANGHAI PUYI) CO Ltd
Priority to CN201610614438.8A priority Critical patent/CN107674039A/en
Publication of CN107674039A publication Critical patent/CN107674039A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明涉及一种可比西他中间体N‑((1R,4R)‑4‑氨基‑5‑苯基‑1‑苄基戊基)氨基甲酸 5‑噻唑基甲基酯(I)的制备方法。该方法以(2R,5R)‑1,6‑二苯基‑2,5‑己二胺二盐酸盐(II)和5‑羟甲基噻唑(III)为原料,在羰基缩合试剂和有机碱的存在下反应,能以较高的收率一步直接得到化合物(I),为N‑((1R,4R)‑4‑氨基‑5‑苯基‑1‑苄基戊基)氨基甲酸 5‑噻唑基甲基酯(I)的制备提供了简洁实用的新方法。 The present invention relates to a kind of N -((1 R ,4 R )-4-amino-5-phenyl-1-benzylpentyl) carbamic acid 5-thiazolyl methyl ester (I) Preparation. The method takes (2R,5R)-1,6-diphenyl-2,5-hexanediamine dihydrochloride (II) and 5-hydroxymethylthiazole (III) as raw materials, in carbonyl condensation reagent and organic Reaction in the presence of base can directly obtain compound (I) in one step with higher yield, which is N -((1 R ,4 R )-4-amino-5-phenyl-1-benzylpentyl) amino The preparation of 5-thiazolylmethyl formic acid (I) provides a simple and practical new method.

Description

一种可比西他中间体的制备方法 A kind of preparation method of copecistat intermediate

技术领域technical field

本发明涉及可比西他中间体的制的制备领域,特别涉及N-((1R,4R)-4-氨基-5-苯基-1-苄基戊基)氨基甲酸 5-噻唑基甲基酯的制备领域。The present invention relates to the field of preparation of copecistat intermediates, in particular to N -((1 R ,4 R )-4-amino-5-phenyl-1-benzylpentyl) carbamic acid 5-thiazolylmethyl The field of preparation of base esters.

背景技术Background technique

可比西他(Cobicistat)是吉利德(Gilead Sciences)公司开发的一种新型的能改善抗HIV药物药动学参数、从而提高药效的增效剂;2012年8月美国FDA首次批准上市。可比西他是细胞色素P450 3A抑制剂,能够抑制参与其他抗HIV药物代谢的肝药酶,尤其是抑制肝药酶对埃替格韦(HIV整合酶抑制剂)的代谢。埃替格韦在与可比西他(Cobicistat)联用后, 能在较低剂量下达到较高血药浓度,从而提高了对病毒抑制的作用并减少了副作用。Cobicistat is a new type of synergist developed by Gilead Sciences that can improve the pharmacokinetic parameters of anti-HIV drugs, thereby increasing the efficacy of the drug; in August 2012, it was first approved by the US FDA for marketing. Copecistat is a cytochrome P450 3A inhibitor, which can inhibit the liver drug enzymes involved in the metabolism of other anti-HIV drugs, especially inhibit the metabolism of liver drug enzymes to eltgravir (HIV integrase inhibitor). After Evitagravir is used in combination with Cobicistat, it can achieve a higher plasma concentration at a lower dose, thereby improving the effect on virus suppression and reducing side effects.

N-((1R,4R)-4-氨基-5-苯基-1-苄基戊基)氨基甲酸 5-噻唑基甲基酯(I)是合成可比西他的关键中间之一。目前合成式(I)的化合物只有下面一种方法。5-thiazolylmethyl N -((1 R ,4 R )-4-amino-5-phenyl-1-benzylpentyl)carbamate (I) is one of the key intermediates in the synthesis of copecistat. The compound of synthetic formula (I) has only the following one method at present.

专利US20100256366A1、WO2015083066A1公开了一种以(2R,5R)-1,6-二苯基-2,5-己二胺二盐酸盐(II)和((5-噻唑基)甲基)-(4-硝基苯基)碳酸酯(IV)为原料,制备N-((1R,4R)-4-氨基-5-苯基-1-苄基戊基)氨基甲酸 5-噻唑基甲基酯(I)的方法。如US20100256366A1的实施例中,以二氯甲烷作溶剂,二异丙基乙基胺作碱,可以83%的收率得到N-((1R,4R)-4-氨基-5-苯基-1-苄基戊基)氨基甲酸 5-噻唑基甲基酯(I)的盐酸盐。Patents US20100256366A1 and WO2015083066A1 disclose a kind of (2 R ,5 R )-1,6-diphenyl-2,5-hexanediamine dihydrochloride (II) and ((5-thiazolyl)methyl) -(4-Nitrophenyl)carbonate (IV) as raw material to prepare N -((1 R ,4 R )-4-amino-5-phenyl-1-benzylpentyl)carbamic acid 5-thiazole The method of methyl ester (I). As in the example of US20100256366A1, using dichloromethane as solvent and diisopropylethylamine as base, N -((1 R ,4 R )-4-amino-5-phenyl can be obtained in 83% yield - 5-thiazolylmethyl 1-benzylpentyl)carbamate (I) hydrochloride.

这种方法看上去虽然比较简单,但((5-噻唑基)甲基)-(4-硝基苯基)碳酸酯(IV)必须以5-羟甲基噻唑(III)为原料,先和羰基缩合试剂与对硝基苯酯反应才能得到,需要两步才能得到产物N-((1R,4R)-4-氨基-5-苯基-1-苄基戊基)氨基甲酸 5-噻唑基甲基酯(I)的盐酸盐,操作略显繁琐。Although this method seems relatively simple, ((5-thiazolyl) methyl)-(4-nitrophenyl)carbonate (IV) must be raw material with 5-hydroxymethylthiazole (III), first and The carbonyl condensation reagent can be reacted with p-nitrophenyl ester, and two steps are required to obtain the product N -((1 R ,4 R )-4-amino-5-phenyl-1-benzylpentyl)carbamate 5- The hydrochloride salt of thiazolyl methyl ester (I) is slightly cumbersome to operate.

发明内容Contents of the invention

对比上述两步法,本发明提供了一种N-((1R,4R)-4-氨基-5-苯基-1-苄基戊基)氨基甲酸 5-噻唑基甲基酯(I)的新方法。Contrast above-mentioned two-step method, the present invention provides a kind of N -((1 R ,4 R )-4-amino-5-phenyl-1-benzylpentyl) carbamic acid 5-thiazolyl methyl ester (I ) of the new method.

该方法简洁实用,以(2R,5R)-1,6-二苯基-2,5-己二胺二盐酸盐(II)和5-羟甲基噻唑(III)为原料,在有机溶剂中,羰基缩合试剂和有机碱的存在下反应,一步直接得到N-((1R,4R)-4-氨基-5-苯基-1-苄基戊基)氨基甲酸 5-噻唑基甲基酯(I)。The method is simple and practical, using (2 R ,5 R )-1,6-diphenyl-2,5-hexanediamine dihydrochloride (II) and 5-hydroxymethylthiazole (III) as raw materials, in In an organic solvent, react in the presence of a carbonyl condensation reagent and an organic base to directly obtain N -((1 R ,4 R )-4-amino-5-phenyl-1-benzylpentyl)carbamic acid 5-thiazole in one step Methyl esters (I).

较佳的,采用的的羰基缩合试剂为三光气、N,N'-二琥珀酰亚胺基碳酸酯(DSC)。Preferably, the carbonyl condensation reagent used is triphosgene and N,N'-disuccinimidyl carbonate (DSC).

较佳的,反应温度为0~30℃。Preferably, the reaction temperature is 0-30°C.

较佳的,反应溶剂为乙腈、二氯甲烷、四氢呋喃。Preferably, the reaction solvent is acetonitrile, dichloromethane, tetrahydrofuran.

较佳的,反应中所用的有机碱为三乙胺、吡啶。Preferably, the organic base used in the reaction is triethylamine and pyridine.

本发明以方便易得的以(2R,5R)-1,6-二苯基-2,5-己二胺二盐酸盐(II)和5-羟甲基噻唑(III)为原料,使用安全、温和反应的条件,为N-((1R,4R)-4-氨基-5-苯基-1-苄基戊基)氨基甲酸 5-噻唑基甲基酯(I)的制备提供了简洁实用的新方法。The present invention uses (2 R ,5 R )-1,6-diphenyl-2,5-hexanediamine dihydrochloride (II) and 5-hydroxymethylthiazole (III) as raw materials , using safe and mild reaction conditions, is the Preparation provides a concise and practical new method.

具体实施方式detailed description

为了能够更清楚地理解本发明的技术内容,特举以下实施例详细说明。In order to understand the technical content of the present invention more clearly, the following examples are given in detail.

实施例1:Example 1:

在干燥的反应瓶中加入二氯甲烷150mL,冷至0℃后加入三光气32.7 g, 并慢慢滴加含有5-羟甲基噻唑38.0g的100mL二氯甲烷溶液,体系于0℃搅拌30min待用。在另一个反应瓶中将(2R,5R)-1,6-二苯基-2,5-己二胺二盐酸盐102.4g,三乙胺100.0g加入600mL二氯甲烷中,冷却到0℃滴加上述三光气制备的溶液, 1小时滴加完毕,反应体系慢慢升温到室温(25℃)后继续搅拌4h;TLC检测原料反应完毕。Add 150mL of dichloromethane into the dry reaction bottle, cool to 0°C, add 32.7 g of triphosgene, and slowly add dropwise 100mL of dichloromethane solution containing 38.0g of 5-hydroxymethylthiazole, and stir the system at 0°C for 30min stand-by. In another reaction flask, 102.4 g of (2 R ,5 R )-1,6-diphenyl-2,5-hexanediamine dihydrochloride and 100.0 g of triethylamine were added to 600 mL of dichloromethane, cooled The solution prepared by the above-mentioned triphosgene was added dropwise at 0°C, and the dropwise addition was completed in 1 hour. The reaction system was slowly warmed up to room temperature (25°C) and then stirred for 4 hours; TLC detected that the reaction of the raw materials was complete.

加入1 mol/L的氢氧化钠水溶液500mL猝灭反应,有机相依次用水、饱和氯化钠溶液洗涤,无水硫酸镁干燥,浓缩溶剂,得到的残余物溶于异丙醇中,并加入异丙醇的盐酸溶液成盐,出现大量白色固体,过滤、润洗、干燥得到白色粉末状产物N-((1R,4R)-4-氨基-5-苯基-1-苄基戊基)氨基甲酸 5-噻唑基甲基酯盐酸盐(I) 118.5 g,收率88.6%。Add 500 mL of 1 mol/L sodium hydroxide aqueous solution to quench the reaction, wash the organic phase with water and saturated sodium chloride solution successively, dry over anhydrous magnesium sulfate, concentrate the solvent, dissolve the obtained residue in isopropanol, and add isopropanol The hydrochloric acid solution of propanol forms a salt, a large amount of white solid appears, filter, rinse and dry to obtain the white powder product N -((1 R ,4 R )-4-amino-5-phenyl-1-benzylpentyl ) 5-thiazolylmethyl carbamate hydrochloride (I) 118.5 g, yield 88.6%.

1H NMR (300 MHz, CD3OD) δ 9.03 (s, 1H), 7.81 (s, 1H), 7.42-7.14(m,10H), 5.23 (d, J =4.5 Hz, 1H), 4.81 (s, 5H), 3.68 (m, 1H), 3.61 (m, 1H), 3.30(m, 1H), 2.81-2.63 (m, 2H), 1.82-2.39 (m, 4H); 19F NMR (300 MHz, CDCl3): δ –197.2 (d, J = 48.5Hz, 1F). 1 H NMR (300 MHz, CD 3 OD) δ 9.03 (s, 1H), 7.81 (s, 1H), 7.42-7.14(m,10H), 5.23 (d, J =4.5 Hz, 1H), 4.81 (s , 5H), 3.68 (m, 1H), 3.61 (m, 1H), 3.30(m, 1H), 2.81-2.63 (m, 2H), 1.82-2.39 (m, 4H); 19 F NMR (300 MHz, CDCl 3 ): δ –197.2 (d, J = 48.5Hz, 1F).

MS (ESI) m/z = 410.2 (M++1).MS (ESI) m/z = 410.2 (M + +1).

实施例2:Example 2:

在干燥的反应瓶中加入乙腈50mL,冷至0℃后加入N,N'-二琥珀酰亚胺基碳酸酯(DSC)28.2 g, 并慢慢滴加含有5-羟甲基噻唑12.7.0g的50mL乙腈溶液,体系于0℃搅拌1小时待用。在另一个反应瓶中将(2R,5R)-1,6-二苯基-2,5-己二胺二盐酸盐34.1g,吡啶25.0g加入200mL乙腈中,冷却到0℃滴加上述DSC制备的溶液, 1小时滴加完毕,反应体系慢慢升温到室温(25℃)后继续搅拌8h;TLC检测原料反应完毕。Add 50mL of acetonitrile into the dry reaction flask, cool to 0°C, add 28.2 g of N,N'-disuccinimidyl carbonate (DSC), and slowly dropwise add 12.7.0 g of 5-hydroxymethylthiazole 50 mL of acetonitrile solution, and the system was stirred at 0°C for 1 hour for use. In another reaction flask, add 34.1 g of (2 R ,5 R )-1,6-diphenyl-2,5-hexanediamine dihydrochloride and 25.0 g of pyridine into 200 mL of acetonitrile, cool to 0°C and drop Add the solution prepared by DSC above, and the dropwise addition is completed in 1 hour. The reaction system is slowly warmed up to room temperature (25°C) and then stirred for 8 hours; TLC detects that the reaction of the raw materials is complete.

浓缩除去大部分乙腈,再加入1 mol/L的氢氧化钠水溶液150mL,再用乙酸乙酯萃取三次,合并的有机相依次用水、饱和氯化钠溶液洗涤,无水硫酸镁干燥,浓缩溶剂,得到的残余物溶于异丙醇中,并加入异丙醇的盐酸溶液成盐,出现大量白色固体,过滤、润洗、干燥得到白色粉末状产物N-((1R,4R)-4-氨基-5-苯基-1-苄基戊基)氨基甲酸 5-噻唑基甲基酯盐酸盐(I) 36.0 g,收率80.7%。Concentrate to remove most of the acetonitrile, then add 150 mL of 1 mol/L sodium hydroxide aqueous solution, and extract three times with ethyl acetate, the combined organic phases are washed with water and saturated sodium chloride solution successively, dried over anhydrous magnesium sulfate, and the solvent is concentrated. The obtained residue was dissolved in isopropanol, and added with hydrochloric acid solution of isopropanol to form a salt, a large amount of white solid appeared, filtered, rinsed and dried to obtain a white powder product N -((1 R ,4 R )-4 -Amino-5-phenyl-1-benzylpentyl) carbamic acid 5-thiazolyl methyl ester hydrochloride (I) 36.0 g, yield 80.7%.

谱图数据见实施例1。See Example 1 for spectrogram data.

在此说明书中,本发明已参照其特定的实施例作了描述。但是,很显然仍可以作出各种修改和变换而不背离本发明的精神和范围。因此,说明书应被认为是说明性的而非限制性的。In this specification, the invention has been described with reference to specific embodiments thereof. However, it is obvious that various modifications and changes can be made without departing from the spirit and scope of the invention. Accordingly, the specification should be regarded as illustrative rather than restrictive.

Claims (5)

1.一种可比西他中间体N-((1R,4R)-4-氨基-5-苯基-1-苄基戊基)氨基甲酸 5-噻唑基甲基酯(I)的制备方法,该方法以(2R,5R)-1,6-二苯基-2,5-己二胺二盐酸盐(II)和5-羟甲基噻唑(III)为原料,在有机溶剂中,羰基缩合试剂和有机碱的存在下反应得到式(I)的化合物。1. Preparation of a copecistat intermediate N -((1 R ,4 R )-4-amino-5-phenyl-1-benzylpentyl)carbamate 5-thiazolylmethyl ester (I) The method uses (2 R ,5 R )-1,6-diphenyl-2,5-hexanediamine dihydrochloride (II) and 5-hydroxymethylthiazole (III) as raw materials. In a solvent, react in the presence of a carbonyl condensation reagent and an organic base to obtain a compound of formula (I). 2.根据权利要求1所述的方法,其特征在于,所述的羰基缩合试剂为三光气、N,N'-二琥珀酰亚胺基碳酸酯(DSC)。2. The method according to claim 1, characterized in that, the carbonyl condensation reagent is triphosgene, N,N'-disuccinimidyl carbonate (DSC). 3.根据权利要求1所述的方法,其特征在于,所述的反应温度为0~30℃。3. The method according to claim 1, characterized in that, the reaction temperature is 0-30°C. 4.根据权利要求1所述的方法,其特征在于,所述的有机溶剂包括乙腈、二氯甲烷、四氢呋喃。4. method according to claim 1, is characterized in that, described organic solvent comprises acetonitrile, methylene dichloride, tetrahydrofuran. 5.根据权利要求1所述的方法,其特征在于,所述的有机碱包括三乙胺、吡啶。5. method according to claim 1, is characterized in that, described organic base comprises triethylamine, pyridine.
CN201610614438.8A 2016-08-01 2016-08-01 A kind of preparation method than his western intermediate Pending CN107674039A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610614438.8A CN107674039A (en) 2016-08-01 2016-08-01 A kind of preparation method than his western intermediate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610614438.8A CN107674039A (en) 2016-08-01 2016-08-01 A kind of preparation method than his western intermediate

Publications (1)

Publication Number Publication Date
CN107674039A true CN107674039A (en) 2018-02-09

Family

ID=61133028

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610614438.8A Pending CN107674039A (en) 2016-08-01 2016-08-01 A kind of preparation method than his western intermediate

Country Status (1)

Country Link
CN (1) CN107674039A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008010921A2 (en) * 2006-07-07 2008-01-24 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CN102438982A (en) * 2009-04-03 2012-05-02 吉里德科学公司 Process for the preparation of cytochrome P450 monooxygenase inhibitors and intermediates involved

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008010921A2 (en) * 2006-07-07 2008-01-24 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CN102438982A (en) * 2009-04-03 2012-05-02 吉里德科学公司 Process for the preparation of cytochrome P450 monooxygenase inhibitors and intermediates involved

Similar Documents

Publication Publication Date Title
JP6386171B2 (en) Novel aminoalkylbenzothiazepine derivatives and uses thereof
CN110041327B (en) Pyridone derivative, composition thereof and application of pyridone derivative as anti-influenza virus medicament
CA2731789C (en) Alkyl thiazole carbamate derivatives, preparation thereof, and use thereof as faah enzyme inhibitors
FR2932483A1 (en) COMPOUNDS USEFUL FOR THE TREATMENT OF CANCERS.
KR20130008050A (en) Method and process for preparation and production of deuterated ω-diphenylurea
JP2007261945A (en) Thiazole derivative
CN113831338B (en) Histone deacetylase inhibitor and preparation method and application thereof
JP2011529480A (en) Polymorphism of rasagiline mesylate
EP2516383B1 (en) New aminotetraline derivatives
US10538507B2 (en) Preparation process for high-purity dabigatran etexilate
JP2018501268A (en) Tizoxanide phosphate and alkane sulfonate and pharmaceutical use thereof
CA2663080A1 (en) Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof
CN107674039A (en) A kind of preparation method than his western intermediate
CN103923058B (en) A kind of method synthesizing Wei Lanteluo intermediate and salt thereof
CN104910068B (en) A kind of synthetic method of the tosilate of 2 cyano group isonicotinic acid hydrazide 1.5
WO2016132296A1 (en) A process for the preparation of an intermediate of dabigatran etexilate
JP2005538126A5 (en)
WO2014092514A1 (en) Novel compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient
KR101698124B1 (en) Process for preparing 3-(methylamino)-3-((R)-pyrrolidin-3-yl)propanenitrile or its salt
CN103012319B (en) Repaglinide intermediate synthesis process improvement
JP6923112B2 (en) Biarylsulfonamide derivative with filovirus cell invasion inhibitory activity
CN104910047A (en) Preparation method of dabigatran etexilate intermediate
CN115806503B (en) A selective histone deacetylase inhibitor and its preparation method and application
CN108329236A (en) A kind of preparation method of the miscellaneous Shandong amine intermediate of grace
RU2741389C1 (en) Method for preparing intermediate compound for synthesis of medicinal agent

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180209